Vir doses first patient in VIR-5500 prostate cancer expansion study

April 13, 2026 8:05 AM

Vir Biotechnology Inc. (NASDAQ: VIR) has dosed the first patient in expansion cohorts of its Phase 1 trial evaluating VIR-5500 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found